Antares Pharma Inc. (ATRS)

Trade ATRS now with
1/27/2020 7:08:07 AM Antares Pharma Sets 2020 Full-year Net Revenue Guidance Of $135 Mln-$155 Mln
12/10/2019 7:07:59 AM Antares Pharma Names Edward Tykot SVP, Corporate Development
11/19/2019 1:06:47 AM Antares Pharma Enters Global Development Agreement With Idorsia Pharma
12/13/2018 7:02:58 AM Antares Pharma Appoints Peter Greenleaf To Board Of Directors
11/29/2018 7:02:29 AM Ntares Pharma Announces Commercial Availability Of XYOSTED Injection
11/6/2018 7:04:55 AM Antares Pharma Q3 Net Loss Narrows To $1.9 Mln From $5.5 Mln Last Year
10/1/2018 7:02:50 AM Antares Gets FDA Approval Of Xyosted Injection For Testosterone Replacement Therapy In Adult Males
9/20/2018 5:56:23 AM D-Day Nearing For Antares Pharma
8/16/2018 5:03:18 PM Antares Pharma Announces FDA Approval Of Generic EpiPen Utilizing VIBEX Auto Injector
8/7/2018 7:06:57 AM Antares Pharma Q2 Loss/shr Widens To $0.03 From $0.02 Last Year
8/6/2018 4:31:11 PM Antares Pharma Appoints James Tursi As EVP, Head Of Research & Development, Chief Medical Officer